No significant differences existed between the UBE2N-negative and UBE2N-positive groups with respect to age (64 vs. 69 years, p = 0.497), tumor stage (p = 0.516), dichotomized tumor stage (p = 0.744), lymph node stage (p = 0.540), survival status (p = 0.337) or follow-up (p = 0.446). This evidence concerns the gene UBE2N and neoplasm.